Price-Gouging Pharma CEO Martin Shkreli: I’ll Lower The Cost Of That AIDS Drug

But he won’t say by how much. NBC News reports:

The pharmaceutical company boss under fire for increasing the price of the drug Daraprim by more than 5,000 percent said Tuesday he will lower the cost of the life-saving medication. Martin Shkreli did not say what the new price would be, but expected a determination to be made over the next few weeks. He told NBC News that the decision to lower the price was a reaction to outrage over the increase in the price of the drug from $13.50 to $750 per pill. “Yes it is absolutely a reaction — there were mistakes made with respect to helping people understand why we took this action, I think that it makes sense to lower the price in response to the anger that was felt by people,” Shkreli, 32, said. Turing Pharmaceuticals of New York bought the drug from Impax Laboratories in August for $55 million and raised the price. Shkreli said Tuesday the price would be lowered to allow the company to break even or make a smaller profit.

Daraprim is used to fight toxoplasmosis, a parasitic infection that killed many during the early years of the AIDS pandemic.